Mivacron (Mivacurium)

Mivacurium, the active ingredient in Mivacron, is a neuromuscular blocking agent presented as a sterile injectable solution for intravenous use. It provides short‑acting skeletal muscle relaxation to facilitate endotracheal intubation and to support surgical procedures. GNH USA supplies Mivacron as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mivacurium is a neuromuscular blocking agent used to produce rapid, short‑duration muscle relaxation in peri‑operative settings.

- Facilitation of endotracheal intubation: provides brief muscle relaxation that allows safe placement of the airway tube. - Muscle relaxation during surgery: enables controlled skeletal muscle relaxation for operative procedures. - Adjunct to general anesthesia: supports induction of anesthesia by delivering rapid neuromuscular blockade.

Mivacurium may cause a range of adverse reactions, most of which are related to its histamine‑releasing properties or to prolonged neuromuscular blockade.

Common Side Effects: - Flushing: transient redness of the skin due to histamine release. - Transient hypotension: brief drop in blood pressure, usually self‑limiting. - Bronchospasm: airway narrowing that may cause wheezing, especially in reactive airway disease. - Tachycardia: mild increase in heart rate.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Prolonged neuromuscular blockade: especially in patients with pseudocholinesterase deficiency. - Hyperkalemia: elevated potassium levels in susceptible individuals. - Cardiac arrhythmias: irregular heart rhythms that may be life‑threatening.

When using Mivacron, clinicians should observe several safety measures to minimize risks.

- Assess pseudocholinesterase activity: deficiency can extend drug effect. - Avoid in patients with known hypersensitivity to mivacurium or related compounds. - Monitor cardiovascular status: histamine release may cause hypotension. - Use caution in asthma or reactive airway disease: risk of bronchospasm. - Evaluate concomitant medications that may potentiate neuromuscular blockade. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Mivacron can interact with other agents that influence neuromuscular transmission or cardiovascular function.

Major Interactions (Avoid): - Concurrent use of other neuromuscular blocking agents: additive paralysis. - Anticholinesterase drugs administered before full recovery: may potentiate block. - Magnesium sulfate: enhances neuromuscular blockade.

Moderate Interactions (Monitor Closely): - Inhalational anesthetics: may increase duration of muscle relaxation. - Beta‑adrenergic blockers: can affect hemodynamic response during administration.